<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363168</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00001650</org_study_id>
    <nct_id>NCT00363168</nct_id>
  </id_info>
  <brief_title>Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial</brief_title>
  <official_title>Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to look at the effects of an experimental drug, ranibizumab, on a
      condition called &quot;predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)&quot; due
      to wet age-related macular degeneration.

      A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% of the choroidal
      neovascular lesion is occupied by blood under the retina. We want to find out if injections
      of ranibizumab into the eye will help patients with this condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, interventional case series. A total of 10 patients, seen in the
      Retina Division of the Wilmer Eye Institute, will be enrolled. Subjects will be randomized to
      either 0.3 mg or 0.5 mg intravitreal injections of ranibizumab, which will be performed
      monthly for 3 doses. Further monthly injections are at the discretion of the examiner, and
      may be withheld if there is lack of continued improvement (defined as lack of improvement of
      at least 5 letters on an eye chart compared with 2 previous consecutive visits or lack of
      decrease of the retinal center point thickness of at least 50 microns compared with 2
      previous consecutive visits) or complete success (defined as visual acuity of 20/20 or better
      or retinal center point thickness &lt;225 microns).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters.</measure>
    <time_frame>12 months</time_frame>
    <description>Visual acuity measured prior to first treatment with ranibizumab and at 12 months following the first treatment were compared for each subject enrolled in the study. The 12 month follow-up visual acuity was subtracted from the baseline visual acuity. Avoiding a 15 or more letter loss in visual acuity was considered a successful outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Changes on Funduscopy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein Leakage on Fluorescein Angiography</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Complications Related to Drug or Its Administration</measure>
    <time_frame>12 months after last injection</time_frame>
    <description>Potential complications included:
Deterioration of best-corrected visual acuity by 3 or more lines
Development of intraocular inflammation
Development of elevated intraocular pressure
Development of other ocular or systemic adverse effects.
Subjects were monitored for potential drug-related ocular adverse effects: intraocular inflammation (uveitis), endophthalmitis, central retinal vein occlusion, transient elevation of IOP, acute reduction in the visual acuity, vitreous hemorrhage, injection-site pain, retinal hemorrhage, posterior vitreous detachment, and subconjunctival hemorrhage. Subjects were monitored for potential adverse effects of intravitreal injections: crystalline lens penetration, retinal break and/or detachment, vitreous hemorrhage, inflammation, and infection. Potential systemic adverse effects were captured by monitoring vital functions such as cardiovascular function, nervous system function, renal function, and gastrointestinal function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/0.05 ml dose of ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/0.05 ml dose of ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.3 mg/0.05 ml dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.5 mg/0.05 ml dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Predominantly hemorrhagic subfoveal CNV (at least 50% of the lesion composed of
             hemorrhage) from age-related macular degeneration (AMD) resulting in visual acuity of
             20/40 or worse.

          -  Age greater than 50 years.

          -  Participant must have media clear enough to permit fundus photography, fluorescein
             angiography, and optical coherence tomography.

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from this study:

          -  Known hypersensitivity to humanized monoclonal antibodies

          -  History (within past 6 months) or evidence of severe cardiac disease (apparent in
             electrocardiogram abnormalities, clinical history of unstable angina, acute coronary
             syndrome, myocardial infarction, revascularization procedure within 6 months prior to
             baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).

          -  History of stroke within 6 months of study entry.

          -  Current acute ocular or periocular infection.

          -  Any major surgical procedure within one month of study entry.

          -  Known serious allergies to fluorescein dye.

          -  Previous participation in a clinical trial (for either eye) involving anti-angiogenic
             drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc)
             within last 6 months.

          -  Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or
             device implantation) in the study eye within the last 6 months.

          -  History of subfoveal laser treatment in the study eye.

          -  History of other visually-limiting conditions such as optic neuropathy, amblyopia,
             choroidal neovascularization due to causes other than AMD in the study eye.

          -  Ocular inflammation (including trace or above) in the study eye.

          -  Inability to comply with study or follow up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil M. Bressler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina. 2010 Sep;30(8):1171-6. doi: 10.1097/IAE.0b013e3181dd6d8a.</citation>
    <PMID>20827138</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>April 3, 2012</results_first_submitted>
  <results_first_submitted_qc>September 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Dr. Neil M. Bressler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hemorrhagic Choroidal Neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab Dose A</title>
          <description>0.3 mg/0.05 ml intravitreal injection</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab Dose B</title>
          <description>0.5 mg/0.05 ml intravitreal injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab Dose A</title>
          <description>0.3 mg/0.05 ml intravitreal injection</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab Dose B</title>
          <description>0.5 mg/0.05 ml intravitreal injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters.</title>
        <description>Visual acuity measured prior to first treatment with ranibizumab and at 12 months following the first treatment were compared for each subject enrolled in the study. The 12 month follow-up visual acuity was subtracted from the baseline visual acuity. Avoiding a 15 or more letter loss in visual acuity was considered a successful outcome.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Dose A</title>
            <description>0.3 mg/0.05 ml intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Dose B</title>
            <description>0.5 mg/0.05 ml intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters.</title>
          <description>Visual acuity measured prior to first treatment with ranibizumab and at 12 months following the first treatment were compared for each subject enrolled in the study. The 12 month follow-up visual acuity was subtracted from the baseline visual acuity. Avoiding a 15 or more letter loss in visual acuity was considered a successful outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Changes on Funduscopy</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Thickness Measured by Optical Coherence Tomography (OCT)</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluorescein Leakage on Fluorescein Angiography</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Complications Related to Drug or Its Administration</title>
        <description>Potential complications included:
Deterioration of best-corrected visual acuity by 3 or more lines
Development of intraocular inflammation
Development of elevated intraocular pressure
Development of other ocular or systemic adverse effects.
Subjects were monitored for potential drug-related ocular adverse effects: intraocular inflammation (uveitis), endophthalmitis, central retinal vein occlusion, transient elevation of IOP, acute reduction in the visual acuity, vitreous hemorrhage, injection-site pain, retinal hemorrhage, posterior vitreous detachment, and subconjunctival hemorrhage. Subjects were monitored for potential adverse effects of intravitreal injections: crystalline lens penetration, retinal break and/or detachment, vitreous hemorrhage, inflammation, and infection. Potential systemic adverse effects were captured by monitoring vital functions such as cardiovascular function, nervous system function, renal function, and gastrointestinal function.</description>
        <time_frame>12 months after last injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Dose A</title>
            <description>0.3 mg/0.05 ml intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Dose B</title>
            <description>0.5 mg/0.05 ml intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Complications Related to Drug or Its Administration</title>
          <description>Potential complications included:
Deterioration of best-corrected visual acuity by 3 or more lines
Development of intraocular inflammation
Development of elevated intraocular pressure
Development of other ocular or systemic adverse effects.
Subjects were monitored for potential drug-related ocular adverse effects: intraocular inflammation (uveitis), endophthalmitis, central retinal vein occlusion, transient elevation of IOP, acute reduction in the visual acuity, vitreous hemorrhage, injection-site pain, retinal hemorrhage, posterior vitreous detachment, and subconjunctival hemorrhage. Subjects were monitored for potential adverse effects of intravitreal injections: crystalline lens penetration, retinal break and/or detachment, vitreous hemorrhage, inflammation, and infection. Potential systemic adverse effects were captured by monitoring vital functions such as cardiovascular function, nervous system function, renal function, and gastrointestinal function.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab Dose A</title>
          <description>0.3 mg/0.05 ml intravitreal injection</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab Dose B</title>
          <description>0.5 mg/0.05 ml intravitreal injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neil M. Bressler</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-8342</phone>
      <email>nbressler@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

